Abstract: Methods of treating a valvular heart disease are provided. Methods for treating valvular heard disease include administering to a subject a therapeutically effective amount of at least one hedgehog pathway inhibitor. Also provided are methods for reducing fibrosis in a subject, which comprise administering to the subject a therapeutically effective amount of at least one hedgehog pathway inhibitor.

Abstract: A transistor includes a substrate, a semiconductor unit disposed on the substrate, a gate unit, a source electrode and a drain electrode. The gate unit includes a non-metal gate part disposed on the semiconductor unit, and a metal gate layer entirely enclosing the non-metal gate part. The drain and source electrodes are disposed respectively on two opposite sides of the gate unit.

Abstract: Systems and methods in accordance with many embodiments of the invention include a motion evaluation system that trains a model to evaluate motion (such as, but not limited to, gait) through images (or video) captured by a single image capture device. In certain embodiments, motion evaluation includes predicting clinically relevant variables from videos of patients walking from keypoint trajectories extracted from the captured images.

Abstract: The deformable body according to the present invention includes a substrate in which a hole is formed, a disc disposed above the hole, and a plurality of hinges protruding from a side surface of the disc and connecting the disc and the substrate.

Abstract: The invention relates to the application of a composition containing recombinant amelogenin and propylene glycol alginate (“PGA”) on to cut dentin tubules followed by installation of a definitive restorative in a single visit.

Abstract: New synthetic methods to provide access to previously unexplored functionality at the C8 position of imidazotetrazines. Through synthesis and evaluation of a suite of compounds with a range of aqueous stabilities (from 0.5 to 40 hours), a predictive model for imidazotetrazine hydrolytic stability based on the Hammett constant of the C8 substituent was derived. Promising compounds were identified that possess activity against a panel of GBM cell lines, appropriate hydrolytic and metabolic stability, and brain-to-serum ratios dramatically elevated relative to TMZ, leading to lower hematological toxicity profiles and superior activity to TMZ in a mouse model of GBM.

Abstract: The present disclosure is directed to methods of treatment, including treatment of a myopathy by administering to a subject in need thereof an elastase inhibitor in combination with a glucocorticoid. The present disclosure is also directed to pharmaceutical compositions that include an elastase inhibitor that can be used in such treatment.

Abstract: A defrost or thaw measuring device has a dumbbell or hourglass-shaped rotatable compartment with a cavity, the cavity being partly filled with at least two phase change materials having different melting points. The measuring device may determine the time period of thawing at two or more temperature intervals in the refrigeration space.

Abstract: A technology is described for spatially estimating thermal emissivity. A method can include obtaining spectral emissivity data and satellite imaging data for a geographic area. A weighted emissivity model of emissivity values may be generated for surfaces included in the geographic area from the spectral emissivity data and the satellite imaging data, wherein the spectral emissivity data is mapped to the satellite imaging data to generate the weighted emissivity model. Thermal imaging data for the geographic area may be received from an airborne thermal imaging sensor and a thermal emissivity map can be generated for the geographic area using the thermal imaging data and the weighted emissivity model. The emissivity values from the weighted emissivity model can be used to estimate thermal emissivity values.

Abstract: The present invention provides for a modified virus, such as a recombinant M13 phage, which in an array, such as a film, is capable of producing piezoelectricity. The modified virus comprises a coat protein can displays a negatively charged amino acid sequence. The present invention provides for a device comprising a piezoelectric element comprising a suitable virus, such as the modified virus, a first surface and a second surface, wherein the first surface is in contact with a first electrode and the second surface is in contact with a second electrode, wherein when pressure is applied to the film, the film is capable of generating an electric current. The present invention provides for a method of making the device, and a method for generating electricity using the device.

Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.

Abstract: A scaffold of hollow fibers comprising a mixture of polylactic acid (PLA) and polybutylene succinate (PBS) and cellulose nanofibers (CNF), medical products made of these scaffolds and methods of using the scaffolds in regenerative medicine. A method for producing the scaffolds is also disclosed.

Abstract: In some aspects, the disclosure relates to the reactivation of inactive X chromosomes (Xi). In some embodiments, the disclosure provides compositions and methods for the reactivation of inactive X chromosomes. In some embodiments, the compositions and methods described by the disclosure may be useful for the treatment of dominant X-linked diseases.

Abstract: An Ussing chamber assembly for assessing a tissue sample and for receiving a first fluid and a second fluid during such assessment is disclosed. The Ussing chamber assembly includes an Ussing chamber configured to be separated by the tissue sample into a first chamber portion and a second chamber portion. The assembly includes a first channel in fluidic communication with the first chamber portion, a second channel in fluidic communication with the second chamber portion, and at least three electrical conductors in fluidic communication with the first chamber portion.

Abstract: The present invention discloses a nickel/titanium oxide-silicon oxide catalyst for synthesizing terpinene-4-ol as well as a preparation method and method of synthesizing terpinene-4-ol using the same. The preparation method includes the steps of catalyst preparation, terpinene-4-ol synthesis and the like are disclosed in the present invention. The preparation method includes the following steps: firstly, preparing a mixed colloid of TiO2 and SiO2 by using a sol-gel method, and then centrifuging, washing, drying and roasting is performed to prepare a TiO2—SiO2 binary oxide; then, preparing Ni/TiO2-SiO2 by dipping in a nickel nitrate solution, and preparing a supported catalyst by drying and roasting; and finally, adopting a terpinolene-4, 8-epoxide a raw material, carrying out isomerization under the dual catalytic action of TiO2-SiO2 and Ni of the supported catalyst, and carrying out hydrogenation to prepare terpinene-4-ol.

Abstract: A UAS may use camera-captured ground feature data to iteratively estimate pose change through a Kalman filter. To avoid excessive drift, the UAS may periodically perform a reset by publishing delta pose and covariance as an edge in a global pose graph, by zeroing out the delta pose and covariance. To further improve global pose estimation, two UASs may share range information and associated pose graph information, thereby providing an additional constraint for each UAS to use in its pose graph optimization.

Abstract: A securement device 1 for securely attaching tubular articles 2 to surfaces comprising an anchor pad 3 for placing the securement device 1 on the surface, a substantially cylindrical base 4 on the anchor pad 3 and a screw cap 5 rotatably mountable on the base 4 at a screw mounting 6 defined between the base 4 and the screw cap 5 between an article receiving position and an article gripping position in which radial pressure is applied to the article 2 placed in the securement device 1 to securely hold the article 2 without the use of external adhesive fixings and prevent micro-pistoning of the article 2.

Abstract: The disclosed embodiments relate to the design of a preconcentrator system for preconcentrating air samples. This preconcentrator system includes a plurality of preconcentrators that preconcentrate the air samples prior to chemical analysis, and a delivery structure comprising a manifold that selectively routes a sample airflow to the plurality of concentrators so that the plurality of preconcentrators receive a sample airflow concurrently or individually.

Abstract: A method of controlling a trajectory of a perpendicular magnetization switching of a ferromagnetic layer using spin-orbit torques in the absence of any external magnetic field includes: injecting a charge current Je through a heavy-metal thin film disposed adjacent to a ferromagnetic layer to produce spin torques which drive a magnetization M out of an equilibrium state towards an in-plane of a nanomagnet; turning the charge current Je off after te seconds, where an effective field experienced by the magnetization of the ferromagnetic layer Heff is significantly dominated by and in-plane anisotropy Hkx, and where M passes a hard axis by precessing around the Heff; and passing the hard axis, where Heff is dominated by a perpendicular-to-the-plane anisotropy Hkz, and where M is pulled towards the new equilibrium state by precessing and damping around Heff, completing a magnetization switching.

Abstract: The present invention provides, inter alia, methods for treating, preventing, or ameliorating the effects of a lymphoid malignancy, such as those associated with a mutated phosphatase and tensin homolog (PTEN) gene, or T-cell acute lymphoblastic leukemia (T-ALL). These methods include administering to a subject an effective amount of a phosphoinositide 3-kinase-delta (PI3K?) inhibitor and a phosphoinositide 3-kinase-gamma (PI3K?) inhibitor. The present invention also provides pharmaceutical compositions for treating the effects of a lymphoid malignancy. This invention further provides a method for identifying a subject who may benefit from co-treatment with a PI3K? inhibitor and a PI3K? inhibitor. This method includes determining from a sample of the subject whether the subject has a mutated PTEN gene. Additionally, this invention provides methods for identifying a compound that has both PI3K? and PI3K? inhibitory activity.